Here's something you might be interested in.
Ask a Hipster — Advice you didn't know you needed
Big Screen — Movie commentary
Blurt — Music's inside track
Booze News — San Diego spirits
Classical Music — Immortal beauty
Classifieds — Free and easy
Cover Stories — Front-page features
Drinks All Around — Bartenders' drink recipes
Excerpts — Literary and spiritual excerpts
Feast! — Food & drink reviews
Feature Stories — Local news & stories
Fishing Report — What’s getting hooked from ship and shore
From the Archives — Spotlight on the past
Golden Dreams — Talk of the town
The Gonzo Report — Making the musical scene, or at least reporting from it
Letters — Our inbox
Movies@Home — Local movie buffs share favorites
Movie Reviews — Our critics' picks and pans
Musician Interviews — Up close with local artists
Neighborhood News from Stringers — Hyperlocal news
News Ticker — News & politics
Obermeyer — San Diego politics illustrated
Outdoors — Weekly changes in flora and fauna
Overheard in San Diego — Eavesdropping illustrated
Poetry — The old and the new
Reader Travel — Travel section built by travelers
Reading — The hunt for intellectuals
Roam-O-Rama — SoCal's best hiking/biking trails
San Diego Beer — Inside San Diego suds
SD on the QT — Almost factual news
Sheep and Goats — Places of worship
Special Issues — The best of
Street Style — San Diego streets have style
Surf Diego — Real stories from those braving the waves
Theater — On stage in San Diego this week
Tin Fork — Silver spoon alternative
Under the Radar — Matt Potter's undercover work
Unforgettable — Long-ago San Diego
Unreal Estate — San Diego's priciest pads
Your Week — Daily event picks
CareFusion pays fat fine for engaging in kickbacks
Product uses were not approved by the FDA
(stock photo)
San Diego-based CareFusion Corp. yesterday, January 9, agreed to pay the government $40.1 million to settle allegations that it violated the False Claims Act by paying kickbacks and promoting its products for uses not approved by the Food and Drug Administration. The company provides healthcare products and services in areas such as infection prevention, respiratory care, and operating-room effectiveness.
According to the Department of Justice, the settlement resolves allegations that the company paid $11.6 million in kickbacks to Dr. Charles Denham while Denham was the co-chair of the Safe Practices Committee at the National Quality Forum, a nonprofit that recommends standardized health performance measures and practices.
The government says the payments were meant to induce Denham to recommend and promote use of ChloraPrep by healthcare providers. ChloraPrep was approved by the Food and Drug Administration, but the justice department says that between 2009 and 2011, CareFusion knowingly promoted ChloraPrep for uses not approved by the FDA.
CareFusion stock, which trades on the New York Stock Exchange, closed yesterday at $41.25. This morning, the stock is down 0.48 percent, or 20 cents, in early trading.
Here's something you might be interested in.
CareFusion pays fat fine for engaging in kickbacks
Product uses were not approved by the FDA
CareFusion pays fat fine for engaging in kickbacks
Product uses were not approved by the FDA
(stock photo)
San Diego-based CareFusion Corp. yesterday, January 9, agreed to pay the government $40.1 million to settle allegations that it violated the False Claims Act by paying kickbacks and promoting its products for uses not approved by the Food and Drug Administration. The company provides healthcare products and services in areas such as infection prevention, respiratory care, and operating-room effectiveness.
According to the Department of Justice, the settlement resolves allegations that the company paid $11.6 million in kickbacks to Dr. Charles Denham while Denham was the co-chair of the Safe Practices Committee at the National Quality Forum, a nonprofit that recommends standardized health performance measures and practices.
The government says the payments were meant to induce Denham to recommend and promote use of ChloraPrep by healthcare providers. ChloraPrep was approved by the Food and Drug Administration, but the justice department says that between 2009 and 2011, CareFusion knowingly promoted ChloraPrep for uses not approved by the FDA.
CareFusion stock, which trades on the New York Stock Exchange, closed yesterday at $41.25. This morning, the stock is down 0.48 percent, or 20 cents, in early trading.
Comments